You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

Investigational Drug Information for AG-348


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug AG-348?

AG-348 is an investigational drug.

There have been 24 clinical trials for AG-348. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2023.

The most common disease conditions in clinical trials are Anemia, Hemolytic, Congenital Nonspherocytic, Anemia, Hemolytic, and Pyruvate Metabolism, Inborn Errors. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and National Institutes of Health Clinical Center (CC).

There are nine US patents protecting this investigational drug and one hundred and thirty-five international patents.

Recent Clinical Trials for AG-348
TitleSponsorPhase
Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesEuroBloodNet AssociationPhase 2
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat StudyAgios Pharmaceuticals, Inc.Phase 4
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionAgios Pharmaceuticals, Inc.Phase 1

See all AG-348 clinical trials

Clinical Trial Summary for AG-348

Top disease conditions for AG-348
Top clinical trial sponsors for AG-348

See all AG-348 clinical trials

US Patents for AG-348

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-348 ⤷  Sign Up Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-348 ⤷  Sign Up Pyruvate kinase activators for use in therapy Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-348 ⤷  Sign Up Methods of using pyruvate kinase activators Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-348 ⤷  Sign Up Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfon- amide Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-348 ⤷  Sign Up Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-348 ⤷  Sign Up Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC (Cambridge, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-348

Drugname Country Document Number Estimated Expiration Related US Patent
AG-348 Argentina AR077292 2029-06-29 ⤷  Sign Up
AG-348 Argentina AR112803 2029-06-29 ⤷  Sign Up
AG-348 Australia AU2010266386 2029-06-29 ⤷  Sign Up
AG-348 Brazil BRPI1011587 2029-06-29 ⤷  Sign Up
AG-348 Canada CA2766882 2029-06-29 ⤷  Sign Up
AG-348 Canada CA2944788 2029-06-29 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.